nach oben

Erschienen in:

10.08.2020 | Allergologie in der HNO-Heilkunde | Übersicht

Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe

verfasst von: Prof. Dr. med. Ludger Klimek, Ingrid Casper, Prof. Dr. med. Karl-Christian Bergmann, Prof. Dr. med. Tilo Biedermann, Jean Bousquet, Peter Hellings, Priv.-Doz. Dr. med. Kirsten Jung, Hans Merk, Heidi Olze, Prof. Dr. med. dDpl.-Ing. Ralph Mösges, Wolfgang Schlenter, Dr. med. Moritz Gröger, Prof. Dr. med. Dr. phil. Johannes Ring, Adam Chaker, Prof. Dr. med. Oliver Pfaar, Prof. Dr. med. Wolfgang Wehrmann, Prof. Dr. med. Torsten Zuberbier, PD Dr. med. Sven Becker

Erschienen in: Allergo Journal | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Auszug

Positionspapier des Ärzteverbandes Deutscher Allergologen (AeDA)^A in Kooperation mit der Sektion HNO der European Academy of Allergy and Clinical Immunology (EAACI)^B, der deutschen ARIA(Allergic Rhinitis and its Impact on Asthma)-Gruppe^C und der Arbeitsgemeinschaft Klinische Immunologie, Allergologie und Umweltmedizin der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC)^D …

Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76

Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH et al; American Academy of Otolaryngic Allergy Working Group on Allergic Rhinitis. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136(6 Suppl):S107-24

Khan MA, Abou-Halawa AS, Al-Robaee AA, Alzolibani AA, Al-Shobaili HA. Daily versus self-adjusted dosing of topical mometasone furoate nasal spray in patients with allergic rhinitis: randomised, controlled trial. J Laryngol Otol 2010;124:397-401

Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E et al; MASK study group. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45

Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017;140:950-8

Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al; ARIA-Arbeitsgruppe. Positionspapier. ARIA-Versorgungspfade für die Allergenimmuntherapie 2019. Allergologie 2019;42:404-25

Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc 2003;24:231-8

Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995;95(5 Pt 2):1097-110

Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy 2015;5:39

10.

Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7

11.

Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy 2015; 70:1372-92

12.

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al; MASK study group*. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol 2016;138:367-74.e2

13.

Interdisziplinäre Arbeitsgruppe "Allergische Rhinitis" der Sektion HNO. Allergische Rhinokonjunktivitis - Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI). Allergo J 2003;12:182-94

14.

Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002;77:350-4

15.

Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75

16.

Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006;96:779-86

17.

Lehtimäki L, Petäys T, Haahtela T. Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol 2009;149:150-3

18.

Stokes JR, Romero FA Jr, Allan RJ, Phillips PG, Hackman F, Misfeldt J et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012;129:409-12,412.e1-2

19.

Kay GG, Quig ME. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc 2001; 22:281-3

20.

Newson-Smith G, Powell M, Baehre M, Garnham SP, MacMahon MT. A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis. Eur Arch Otorhinolaryngol 1997;254:236-41

21.

Mullol J, Bousquet J, Bachert C, Canonica WG, Gimenez-Arnau A, Kowalski ML et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008;63 Suppl 87:5-28

22.

Thorn C, Pfaar O, Hörmann K, Klimek L. Rupatadin - Pharmakologie, klinische Wirksamkeit und therapeutische Sicherheit eines neuen Antihistamins mit zusätzlicher, PAF-antagonisierender Wirkung. Allergologie 2010;33:429-40

23.

Perez I, Villa M, De La Cruz G. Rupatadine in allergic rhinitis: Pooled analysis of efficacy data. Allergy 2002;57:245

24.

Yamamoto H, Yamada T, Kubo S, Osawa Y, Kimura Y, Oh M et al. Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. Allergy Asthma Proc 2010;31:296-303

25.

Sádaba Díaz de Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A. Bilastine for the relief of allergy symptoms. Drugs Today (Barc) 2011;47:251-62

26.

Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L et al.; Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47

27.

Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28

28.

Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM et al.; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65

29.

Yañez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479-84

30.

30. Kaliner MA, Berger WE, Ratner PH, Siegel CJ. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2011;106(2 Suppl):S6-S11

31.

Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol 2009;158:164-73

32.

Klimek L, Högger P, Pfaar O. Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis. Teil 1: Pathophysiologie, molekulare Grundlagen. Mechanism of action of nasal glucocorticosteroids in the treatment of allergic rhinitis. Part 1: Pathophysiology, molecular basis. HNO 2012;60:611-7

33.

Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23

34.

Bernstein JA. Evaluating the effectiveness of medications in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2010;105:189; author reply 189

35.

Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104:13-29

36.

Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG et al.; ARIA Working Group 2019 ARIA Care pathways for allergen immunotherapy. Allergy 2019;74:2087-102

37.

Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S et al.; MASK study group. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin immunol 2019;144:135-43.e6

38.

Bousquet J, Devillier P, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy 2018;73:1763-74

39.

Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62 Suppl 85:17-25

40.

Dalal AA, Stanford R, Henry H, Borah B. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008;101:23-9

41.

Day JH, Briscoe MP, Ratz JD, Danzig M, Yao R. Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol 2009;102:328-38

42.

Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22

43.

Prenner P, Anolik R, Danzig M, Yao R. Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc 2009;30:263-9

44.

Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 2010;120:1718-23

45.

MSD. SINGULAIR^® - Fachinformation (Zusammenfassung der Merkmale der Arzneimittel). MSD Sharp & Dohme GmbH 2019. [URL: https://www.msd.de/fileadmin/files/fachinformationen/singulair.pdf] und [Rote Liste Service GmbH, URL: https://www.patienteninfo-service.de/a-z-liste/s/]

46.

Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, Khattiyawittayakun L, Snidvongs K. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis. Int Forum Allergy Rhinol 2018;8:1083-92

47.

Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. J Allergy Clin Immunol Pract 2018;6:1726-32.e6

48.

Feng S, Fan Y, Liang Z, Ma R, Cao W. Concomitant corticosteroid nasal spray plus antihistamine (oral or local spray) for the symptomatic management of allergic rhinitis. Eur Arch Otorhinolaryngol 2016;273:3477-86

49.

Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81

50.

Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105: 168-73

51.

Leung DY M, Szefler J (Associate Editors of the JACI). The Editors' Choice. J Allergy Clin Immunol 2012;129:1216-7. DOI: https://doi.org/10.1016/j.jaci.2012.03.019

52.

Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33:324-32

53.

Portmann D, Le Gal M, Jessent V, Verrière JL. [Acceptability of local treatment of allergic rhinitis with a combination of a corticoid (beclomethasone) and an antihistaminic (azelastine)]. Rev Laryngol Otol Rhinol (Bord) 2000;121:273-9

54.

Anolik R. Mometasone furoate nasal spray with loratadine study group. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:264-71

55.

Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004;34:259-67

56.

van Galen KA, Nellen JF, Nieuwkerk PT. The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis. AIDS Red Treat 2014;2014:967073

57.

D'Addio AD, Ruiz NM, Mayer MJ, Berger W, Meltzer EO. Quantification of the Distribution of MP29-02 (Dymista-Azelastine HCl/Fluticasone Propionate Nasal Spray) in an Anatomical Model of the Human Nasal Cavity. Poster Session. AAAAI Annual Meeting 2015, Houston, Texas. [URL: https://www.eposters.net/pdfs/quantification-of-the-distribution-of-mp29-02-dymista-azelastine-hclfluticasone-propionate-nasal.pdf]

58.

Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 2007;23:2441-52

59.

Shaw RJ. Pharmacology of fluticasone propionate. Respir Med 1994;88 Suppl A:5-8

60.

Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282-319

61.

Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9.e10

62.

Harrow B, Sedaghat AR, Caldwell-Tarr A, Dufour R. A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines. J Manag Care Spec Pharm 2016;22:1426-36

63.

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9

64.

Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol 2019;122:160-6.e1

65.

Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations. Allergy Asthma Proc 2018;39:224-31

66.

Patel P, Salapatek AM, Talluri RS, Tantry SK. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations. Allergy Asthma Proc 2018;39:232-9

67.

Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 2009;9:933-43

68.

Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8

69.

Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21(1 Pt 2):e160-5

70.

Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al.; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39:271-9

71.

Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007;21:403-10

72.

Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy 2016;71:1219-22

73.

Haahr PA, Jacobsen C, Christensen ME. MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark. Int Forum Allergy Rhinol 2019;9:388-95

74.

Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy 2018;73:1084-93

Titel: Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe
verfasst von: Prof. Dr. med. Ludger Klimek
Ingrid Casper
Prof. Dr. med. Karl-Christian Bergmann
Prof. Dr. med. Tilo Biedermann
Jean Bousquet
Peter Hellings
Priv.-Doz. Dr. med. Kirsten Jung
Hans Merk
Heidi Olze
Prof. Dr. med. dDpl.-Ing. Ralph Mösges
Wolfgang Schlenter
Dr. med. Moritz Gröger
Prof. Dr. med. Dr. phil. Johannes Ring
Adam Chaker
Prof. Dr. med. Oliver Pfaar
Prof. Dr. med. Wolfgang Wehrmann
Prof. Dr. med. Torsten Zuberbier
PD Dr. med. Sven Becker
Publikationsdatum: 10.08.2020
Verlag: Springer Medizin
Schlagwörter: Allergologie in der HNO-Heilkunde
Mastzellstabilisatoren
Allergische Rhinitis
Wirkstoffe
Glucocorticoide
Azelastin
Erschienen in: Allergo Journal / Ausgabe 5/2020
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI: https://doi.org/10.1007/s15007-020-2551-0

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe

Auszug

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Pollenflug oder Corona? Videosprechstunden von Allergikern stark nachgefragt

Erbsenallergie: Pis s 1 ist klinisch relevantes Hauptallergen

Allergien bei Kindern: Frühzeitige spezifische Immuntherapie verhindert atopischen Marsch

Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches*

Snus weniger gefährlich als Rauchen

Mit Hausstaubmilben Asthma vorbeugen

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO